Education
About Us
Working with TipRanks
Follow Us
Pharming Group N.V. (NL:PHARM)
:PHARM
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
>-0.01Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 14.02%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
Pharming had a strong start to 2025 with significant revenue growth and pipeline progression, despite facing some financial challenges due to one-time acquisition costs.Company Guidance
During the Q1 2025 call, Pharming provided optimistic guidance for the fiscal year, highlighting a 42% increase in total revenues and a 49% growth in RUCONEST sales, reaching $68.6 million. Joenja sales rose by 9%, and the company expects further acceleration due to upcoming catalysts like the U.S. pediatric label expansion and international launches. Operating expenses, excluding non-recurring costs related to the Abliva acquisition, were $70.4 million, and the company plans to cut G&A expenses by $10 million annually. Pharming raised its 2025 revenue guidance to between $325 million and $340 million, anticipating a growth of 9% to 14% while maintaining operating expenses flat, excluding Abliva-related costs. The company's pipeline initiatives are set to expand Joenja's potential market and support long-term value creation.Strong Revenue Growth
Total revenues increased by 42% in Q1 2025, driven by a 49% growth in RUCONEST sales and a 9% increase in Joenja sales.
RUCONEST Performance
RUCONEST sales reached $68.6 million, reflecting a continued increase in new patient enrollment and sustained expansion of the prescriber base.
Financial Improvement
Operating loss narrowed significantly year-over-year, with a profit generated for the third consecutive quarter excluding non-recurring expenses.
Pipeline Progress
Initiation and patient enrollment for genetic PID and CVID Phase II studies, along with the resumption of the KL1333 Phase II trial.
Financial Guidance Upgrade
Full-year revenue guidance for 2025 raised to between $325 million and $340 million, implying a growth of 9% to 14%.
---
NL:PHARM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NL:PHARM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | €0.76 | €0.89 | +16.64% |
Mar 13, 2025 | €0.72 | €0.84 | +16.43% |
Oct 24, 2024 | €0.84 | €0.75 | -10.69% |
Aug 01, 2024 | €0.80 | €0.73 | -8.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group N.V. (NL:PHARM) report earnings?
Pharming Group N.V. (NL:PHARM) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Pharming Group N.V. (NL:PHARM) earnings time?
Pharming Group N.V. (NL:PHARM) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pharming Group N.V. stock?
The P/E ratio of Pharming Group is N/A.
What is NL:PHARM EPS forecast?
NL:PHARM EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.
---